Displaying drugs 526 - 550 of 11537 in total
Artemisia absinthium pollen
Artemisia absinthium pollen is the pollen of the Artemisia absinthium plant. Artemisia absinthium pollen is mainly used in allergenic testing.
Approved
Buspirone
Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does...
Approved
Investigational
Matched Description: … Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. ... Belonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT1A ... It has also been used as a second-line therapy for unipolar depression when the use of selective serotonin …
Methyldopa
Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading...
Approved
Matched Description: … Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. ... [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug …
Indacaterol
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. ... Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis …
Human interferon beta
Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life. Interferon...
Approved
Investigational
Matched Description: … significantly debilitating with a profound impact on the quality of life. ... Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis ... It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity. …
Satralizumab
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL- ... [L15536] Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare ... "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors occurs in a …
Efmoroctocog alfa
Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as DB13999 . It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It...
Approved
Investigational
Matched Description: … Haemophilia A is a rare bleeding disorder associated with a slow clotting process caused by the deficiency ... Factor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood ... Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life …
Fosdenopterin
Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … resulting from a lack of SOX activity. ... the first therapeutic option for patients with MoCD type A. ... Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a …
Lopinavir
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with ritonavir - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability...
Approved
Matched Description: … [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold ... Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration …
Saxagliptin
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Approved
Safinamide
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Approved
Investigational
Matched Categories: … Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates …
Remestemcel-L
Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was...
Approved
Investigational
Matched Description: … risk for poor outcomes and creating a significant clinical challenge [A31818]. ... Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal ... aGvHD is a T-cell mediated disease that occurs after allogeneic hematopoietic stem cell transplant and …
Methysergide
An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the...
Approved
Matched Description: … An ergot derivative that is a congener of lysergic acid diethylamide. …
Thonzonium
Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. A common pharmaceutical formulation of thonzonium bromide is...
Approved
Matched Description: … Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. ... A common pharmaceutical formulation of thonzonium bromide is cortisporin-TC ear drops. …
Viltolarsen
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) ... links between nucleotides are replaced with a phosphorodiamidate linkage. ... Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of …
Ertugliflozin
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Matched Description: … Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes …
Ethotoin
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread...
Approved
Matched Description: … Ethotoin is a hydantoin derivative and anticonvulsant. …
Adalimumab
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … [L49101] A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available ... It is produced by recombinant DNA technology using a mammalian cell expression system. ... Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid …
Asparagine
A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)
Approved
Investigational
Nutraceutical
Matched Description: … A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain …
Alclofenac
Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
Approved
Withdrawn
Matched Description: … Alclofenac is a non-steroidal anti-inflammatory drug. …
Apronalide
Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura .
Approved
Atracurium
Approved
Experimental
Investigational
Crotalus adamanteus antivenin
Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age group of 18 to 28 .
The eastern diamondback...
Approved
Experimental
Chlorpropamide
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class...
Approved
Investigational
Paroxetine
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline...
Approved
Investigational
Matched Description: … Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. ... It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic ... [L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition …
Displaying drugs 526 - 550 of 11537 in total